Almost every robot we price on this site has to be reverse-engineered from dealer carts, because manufacturers will not publish a number. Medical exoskeletons are the exception. Medicare publishes what it will pay, to the cent, in a public-use file anyone can download — and for a whole category of wearable robots that published number is effectively the market price.
On 5 August 2026 we downloaded the January 2026 DMEPOS fee schedule directly from CMS and pulled the powered-exoskeleton codes out of it. Here is what the US government says a medical exoskeleton is worth.
The 2026 numbers
| HCPCS | What it covers | Floor | **Fee schedule amount** | Ceiling |
|---|---|---|---|---|
| **K1007** | Bilateral hip-knee-ankle-foot device, powered, with pelvic component, motors, microprocessors, sensors — i.e. a personal walking exoskeleton | $85,572.93 | **$95,081.03** | $114,097.24 |
| **L8702** | Powered upper-extremity assist device: elbow, wrist, hand **and finger** | $61,921.54 | **$68,801.71** | $82,562.05 |
| **L8701** | Powered upper-extremity assist device: elbow, wrist, hand | $31,473.12 | **$34,970.13** | $41,964.16 |
| *L2005* | *Conventional mechanical KAFO, single/double upright — the non-powered comparator* | *$4,499.86* | *$5,063.24* | *$5,999.81* |
K1007 is the code the ReWalk personal exoskeleton bills under. L8701 and L8702 are the codes CMS created for the MyoPro powered arm orthosis, corresponding to the Motion W and Motion G configurations respectively.
Three observations that are not published anywhere else.
The powered codes have one national price; ordinary braces do not. In the same file, the conventional KAFO code L2005 carries eight distinct state-level amounts and the L2040 orthotic carries eleven. K1007, L8701 and L8702 each carry a single figure that is identical in every state and territory. These devices were priced by gap-filling rather than by the historical regional fee data that drives the rest of the schedule, and the result is that a powered exoskeleton costs Medicare exactly the same in Mississippi as in Manhattan.
The ceiling and floor are mechanical, not negotiated. For all three powered codes the ceiling is exactly 1.20x the fee and the floor is exactly 0.90x. There is no market discovery in those brackets; they are arithmetic.
Powered costs 18.8x mechanical. $95,081.03 against $5,063.24 for a conventional KAFO doing the same anatomical job without motors. That multiple is the cleanest answer we have seen to "what does adding actuation cost" in any robot category.
What the patient pays
Medicare Part B pays 80% of the fee schedule amount after the annual deductible; the beneficiary is responsible for the remaining 20% coinsurance unless a supplemental plan covers it. Applying that to the 2026 amounts — our calculation, not a CMS-published figure:
| Code | Medicare pays (80%) | Patient coinsurance (20%) |
|---|---|---|
| K1007 | $76,064.82 | **$19,016.21** |
| L8702 | $55,041.37 | **$13,760.34** |
| L8701 | $27,976.10 | **$6,994.03** |
A $19,016 coinsurance bill is not a rounding error, and it is the number a prospective user actually needs. It is also why manufacturer marketing tends to lead with "covered by Medicare" rather than with a price.
These prices are indexed, not repriced
When the fees were finalised effective 1 April 2024, the amounts were $91,032 for K1007, $33,480.90 for L8701 and $65,871.74 for L8702. Divide the January 2026 figures by those:
- K1007: 95,081.03 / 91,032 = 1.044479
- L8701: 34,970.13 / 33,480.90 = 1.044479
- L8702: 68,801.71 / 65,871.74 = 1.044479
All three moved by an identical 4.4479%. That is the covered-item update compounding, applied uniformly — not any reassessment of what these devices cost or what they are worth. Between April 2024 and January 2026 the ReWalk generation changed (the ReWalk 7 received FDA clearance in March 2025) and the market grew, and the price responded to none of it. If you are modelling this category, treat the fee as an inflation-indexed constant, not as a signal.
The identical ratio is also a useful cross-check on the April 2024 K1007 figure, which is harder to source directly than the L-codes: it lands on exactly the same multiplier as two independently reported numbers.
What manufacturers actually realise
The fee schedule is what Medicare pays, not what the company banks. Myomo is the one manufacturer in this category that publishes the arithmetic, and its most recent full-year results give an unusually clear picture.
| Myomo, Q4 2025 | Figure |
|---|---|
| Units with revenue recognised | 208 |
| Average selling price | ~$54,600 |
| Revenue | $11,353,296 |
| Cost of revenue | $3,569,021 |
| Implied cost per unit | **$17,159** |
| Gross margin | **68.6%** |
| Medicare Part B share of revenue | 49% |
Full-year 2025 revenue was $40,928,042, up 26%, with cost of revenue of $14,039,718 — a 65.7% full-year gross margin. Guidance for 2026 is $43-46 million.
Two things follow. First, a blended ASP of about $54,600 sits between the L8701 amount of $34,970.13 and the L8702 amount of $68,801.71, which implies a mix of roughly 58% of the higher-coded device — our inference from the two published fees, not a company disclosure. Second, the device costs about $17,159 to make and is reimbursed at $34,970-$68,802. In a category where the price is set administratively and cannot be competed down, that spread is what the fee schedule is buying: it funds the clinical, fitting and reimbursement-navigation apparatus, not just the hardware.
Devices that are not on the fee schedule
Clinic-based rehabilitation exoskeletons — EksoNR and Ekso Indego Therapy, for example — are capital equipment bought by hospitals and rehab facilities, not billed to a patient's DME benefit, so they have no fee schedule amount. Reported list prices for clinical systems cluster around $100,000-$150,000, but these are secondary figures from device-industry coverage rather than manufacturer or dealer pages, and we could not confirm them against a primary source. Treat them as indicative only. Ekso Bionics' total 2024 revenue was $17.9 million across its entire product line, which is worth holding in mind before assuming large installed volumes at those prices.
Industrial and construction exoskeletons are a completely different price class — $1,499 to about $2,199 for the passive and tool-support devices we priced in the Hilti exoskeleton price guide. A powered medical exoskeleton costs roughly 43 to 63 times a passive industrial one. They are not competing products and should never appear in the same price range.
Buying notes
The fee schedule is the price, so shop the process, not the number. No supplier can beat $95,081.03, and none will come in under it in a way that helps you. What varies is whether the provider can get the prior authorisation approved.
Confirm code verification. Since 1 June 2024, only products that have completed mandatory code verification review may be billed under K1007. A device that cannot be billed under the code is a device you pay for entirely yourself.
Budget the coinsurance up front. $19,016.21 on K1007, $13,760.34 on L8702.
Commercial and Medicare Advantage plans set their own rates. The figures here govern traditional Medicare Part B. Advantage plans issue their own prior authorisations and may pay differently.
Browse the category: exoskeleton robots on GrabaRobot.
Sources
- CMS, DMEPOS Fee Schedule public use file DME26-A (January 2026), downloaded 5 August 2026: https://www.cms.gov/medicare/payment/fee-schedules/dmepos/dmepos-fee-schedule/dme26
- CMS, DMEPOS fee schedule April 2026 quarterly update: https://www.cms.gov/files/document/mm14425-dmepos-fee-schedule-april-2026-quarterly-update.pdf
- Myomo, Q4 and full year 2025 results (units, ASP, cost of revenue): https://myomo.com/wp-content/uploads/2026/03/Myomo-Q425-Earnings-PR.pdf
- Myomo, CMS final Medicare DMEPOS fee schedule rate for MyoPro (April 2024 L8701/L8702 amounts): https://myomo.com/cms-posts-final-medicare-dmepos-fee-schedule-rate-myopro/
- Noridian DME MAC, powered lower extremity exoskeleton correct coding (K1007 scope and code verification requirement): https://med.noridianmedicare.com/web/jddme/policies/dmd-articles/2023/powered-lower-extremity-exoskeleton-correct-coding
- PDAC, MyoPro assist device correct coding (L8701/L8702 device mapping): https://www.dmepdac.com/palmetto/PDACv2.nsf/DIDC/QPJCHCVJLF~Articles%20and%20Publications~Advisory%20Articles
- Lifeward, CMS preliminary reimbursement determination for the ReWalk personal exoskeleton: https://ir.rewalk.com/news-releases/news-release-details/historic-move-medicare-proposes-preliminary-reimbursement-level
- AOPA, 2026 Medicare DMEPOS fee schedule update: https://aopanet.org/2026-medicare-dmepos-fee-schedule-update/
Limitations. Fee schedule amounts are the January 2026 file; CMS updates quarterly, so verify before relying on them for a claim. The coinsurance figures are our arithmetic on the published fees and assume the annual deductible has been met and no secondary coverage applies. The clinical-system price range is not primary-sourced and is flagged as such. Myomo's ASP is a company-reported blended figure across both codes and geographies, not a list price.
